Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2026 03:30 ET | Source: FundaMental Pharma GmbH

FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate

FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as CMO to advance FMP374 toward the clinic in treatment-resistant depression.
February 17, 2026 03:30 ET | Source: FundaMental Pharma GmbH

FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference

FundaMental Pharma chosen among twelve companies to showcase its groundbreaking TRD candidate, FMP374, at the Bio-Neuroscience Conference.